ENGAGE-501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

被引：0
|
作者：
Younes, Anas [1 ]
Hernandez, Francisco [2 ,3 ]
Bociek, R. Gregory [4 ]
Kasamon, Yvette L. [5 ]
Lee, Peter [6 ]
Gore, Lia [7 ]
Buglio, Daniela [8 ]
Copeland, Amanda [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Clin Invest & Translat Res Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Immunol Canc Cell Ctr, Buffalo, NY 14263 USA
[4] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Tower Canc Res Fdn, Beverly Hills, CA USA
[7] Univ Colorado Canc Ctr, Aurora, CO USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[9] Univ Texas Houston, MD Anderson Canc Ctr Hymphoma Myeloma, Houston, TX USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1614 / 1615
页数：2
相关论文
共 50 条
  • [41] Interim analysis of a phase II study of the combination of denileukin diftitox (Ontak) and rituximab for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
    Dang, NH
    McLaughlin, P
    Fayad, L
    Romaguera, J
    Hagemeister, F
    Younes, A
    Neelapu, S
    Samaniego, F
    Jones, D
    Walker, PL
    Rodriguez, MA
    Kwak, L
    Pro, B
    BLOOD, 2005, 106 (11) : 936A - 936A
  • [42] A Phase 1-2 Study of Brentuximab Vedotin (Bv) and Bendamustine (B) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL)
    O'Connor, Owen A.
    Kuruvilla, John
    Sawas, Ahmed
    Deng, Changchun
    Patterson, Molly
    Connors, Joseph M.
    Amengual, Jennifer E.
    Crump, Michael
    Villa, Diego
    BLOOD, 2014, 124 (21)
  • [43] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin's lymphoma results of multicenter phase II study
    Josting, A
    Sieniawski, M
    Staak, J
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 : 183 - 183
  • [44] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, A.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Crump, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 162 - 162
  • [45] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
    Yuqin Song
    Quanli Gao
    Huilai Zhang
    Lei Fan
    Jianfeng Zhou
    Dehui Zou
    Wei Li
    Haiyan Yang
    Ting Liu
    Quanshun Wang
    Fangfang Lv
    Haiyi Guo
    Liudi Yang
    Rebecca Elstrom
    Jane Huang
    William Novotny
    Vivian Wei
    Jun Zhu
    Leukemia, 2020, 34 : 533 - 542
  • [46] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Crump, M.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedgwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
    Song, Yuqin
    Gao, Quanli
    Zhang, Huilai
    Fan, Lei
    Zhou, Jianfeng
    Zou, Dehui
    Li, Wei
    Yang, Haiyan
    Liu, Ting
    Wang, Quanshun
    Lv, Fangfang
    Guo, Haiyi
    Yang, Liudi
    Elstrom, Rebecca
    Huang, Jane
    Novotny, William
    Wei, Vivian
    Zhu, Jun
    LEUKEMIA, 2020, 34 (02) : 533 - 542
  • [48] Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study
    Sureda, Anna
    Pinto, Antonio
    Ghesquieres, Herve
    Morschhauser, Franck
    Tournilhac, Olivier
    Mutseaers, Pim
    Zijlstra, Josee M.
    De Jong, Floris A.
    Janik, Tomas
    Zinzani, Pier Luigi
    BLOOD, 2022, 140 : 3696 - 3697
  • [49] Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children's Oncology Group (COG) report.
    Cole, Peter D.
    McCarten, Kathleen
    Metzger, Monika
    Drachtman, Richard A.
    Horton, Terzah M.
    Pei, Qinglin
    Bush, Rizvan
    Blaney, Susan
    Weigel, Brenda
    Kelly, Kara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive Non-Hodgkin's lymphoma - Results of multicenter phase II study.
    Josting, A
    Sieniawski, M
    Staak, O
    Glossmann, JP
    Diehl, V
    Engert, A
    BLOOD, 2003, 102 (11) : 405A - 405A
12345